Skip to main content
. Author manuscript; available in PMC: 2013 Oct 8.
Published in final edited form as: Biochem Pharmacol. 2011 Feb 1;81(7):881–890. doi: 10.1016/j.bcp.2011.01.017

Figure 5. MLN8237 plus docetaxol inhibits tumor growth in a MCL xenograft mouse model and increases survival.

Figure 5

Figure 5

(A). A MCL Granta-519 xenograft mouse model (n=12 per cohort) shows significant TGI in mice treated with MLN8237 plus docetaxel in a dose-dependent manner in comparison to control (* p < 0.001), MLN8237 or docetaxel alone. The cylinders represent duration of therapy with MLN8237 while the black sphere represents treatment with docetaxel. (B). A MCL Granta-519 xenograft mouse model showed significant overall survival difference with MLN8237 plus docetaxel in comparison to control (** p=0.0003), MLN8237 or docetaxel alone.

HHS Vulnerability Disclosure